June 25, 2020
SNF472 selectively inhibits pathological calcification by binding to hydroxyapatite crystals Palma, Spain and San Diego, USA, 25 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that data examining the mechanism of action of SNF472, Sanifit’s lead compound in development, has been published in the British Journal of...


Experienced neuroscientist at the helm of The Brain Prize
30. June 2020
Eight promising young researchers receive Lundbeck Foundation Fellowships
16. June 2020
Denmark Gets Its First Master’s Degree Programme in Neuroscience
4. June 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge